Rich Heyman, Metacrine chairman (ARCH)
A Rich Heyman biotech backed by a top Salk scientist is auctioned off for its dwindling cash reserves
It’s time to turn off the lights at Metacrine. The party ended months ago.
The Rich Heyman startup $MTCR came out of the IPO gate …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
